Different Expression of HER2/neu Oncogene in Breast Carcinoma and in Liver Metastasis. Description of a Case

2006 ◽  
Vol 92 (6) ◽  
pp. 536-539 ◽  
Author(s):  
Elisa Rossi ◽  
Edda Simoncini ◽  
Francesca Valcamonico ◽  
Giovanni Marini ◽  
Piergiovanni Grigolato ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastasis ◽  
Breast Carcinoma ◽  
Primary Tumor ◽  
Left Breast ◽  
Metastatic Carcinoma ◽  
Adequate Treatment ◽  
Her 2 ◽  
Neu Oncogene ◽  
Liver Ultrasonography

We report the clinical, morphological and molecular findings regarding a 37-year-old woman with breast cancer metastatic to the liver and describe the different expression of a tumor marker in the primary and secondary lesions and the singular responsiveness to treatment. The patient suffered from a carcinoma of the left breast with metastasis to the liver. High HER-2 protein expression assessed by immunohistochemistry and HER-2/neu amplification determined by FISH were present in the primary tumor, while the liver metastasis showed a lower value of HER-2 protein (2+) and absence of HER-2/neu amplification. The patient was treated with chemotherapy (epirubicin and paclitaxel) followed by trastuzumab and docetaxel. After 5 months, at the completion of chemo-immunotherapy, liver ultrasonography showed a further hepatic response. A second biopsy was performed on the residual liver nodule: immunohistochemistry revealed negative (1+) HER-2 expression and FISH confirmed that the HER-2/neu gene was not amplified. The different amplification of HER-2 and expression of its protein in primary and metastatic carcinoma could be important for planning adequate treatment.

Risk factors of local relapses in patients with breast cancer depending on the properties of the primary tumor

2021 ◽  
Vol 43 (3-4) ◽  
pp. 67-73
Author(s):  
O. V. Movchan ◽  
◽  
I. Yu. Bagmut ◽  
I. V. Dosenko ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Primary Tumor ◽  
Main Group ◽  
Control Group ◽  
Histological Structure ◽  
Luminal A ◽  
Luminal B ◽  
Subtype B ◽  
Her 2

Of all a spread of disorders after mastectomy, most frequently we expect about the event of local relapse. The aim – to research the frequency of local relapses in patients with breast carcinoma, considering the subtype properties of the primary tumor. Materials. 6136 patients with breast carcinoma, including 146 patients with LR – main group, and 455 patients without LR – control group. They distributed betting on age, the state of the menstrual function, stage of the disease, histological type of cancer, grade, tumor subtype. Results. In step with the histological structure, ductal carcinoma was commonest. Established the 10-year non-relapse period in main group is longer with Luminal A and Triple-negative subtypes (61 vs 41%) compared to Luminal B and Her-2 / neu type with (3+) amplification (39 % vs 32 % respectively). Conclusions. The stage, histological structure, grade of the tumor does not significantly affect the frequency of local relapses breast cancer patients. The LR is more likely to occur in patients with luminal subtype B, while the littlest frequency of LR occurs with subtype A. Study of the menstrual status of the patient providing local relapses more often arise in women of pre-menopause. Established that the 10-year non-relapse period is that the best in patients with luminal A subtype and TNBC compared to luminal B and HER 2 type with (3+) amplification.

CLINICAL AND HISTOPATHOLOGICAL REVIEW OF INVASIVE BREAST CARCINOMA IN A TERITARY CARE CENTRE.

2021 ◽  
pp. 18-21
Author(s):  
A. Gomathy ◽  
Muruganantham Arunagirinathan ◽  
I. Nithya
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Cancer Survival ◽  
Histological Grade ◽  
Lymph Node Involvement ◽  
Left Breast ◽  
Invasive Breast Carcinoma ◽  
Indian Women ◽  
Node Involvement ◽  
Grade Ii

BACKGROUND: Breast cancer accounts for 14% of all cancers in Indian women, that can occur at any age. Cancer survival becomes more difcult in higher stages of tumour, hence in order to improve the survival of affected persons, early diagnosis of breast cancer is critical. METHODS: Retrospective study of 48 mastectomy specimens with relevant clinical details and respective H&E stained slides were reviewed. CONCLUSION: This review showed that occurrence of Invasive Breast Carcinoma(IBC) peaks in the age group of 41-50years (35.4% ) with right and left breast being affected equally in the ratio of R:L – 1 : 1. Most of the IBC (91.6%) were of No Special Type (NST), with 75% of tumours were of Histological Grade II. 58.3% of tumours were of tumour stage T along with lymph node involvement in equal number of cases.

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

1993 ◽  
Vol 11 (10) ◽  
pp. 1936-1942 ◽  
Author(s):  
R Seshadri ◽  
F A Firgaira ◽  
D J Horsfall ◽  
K McCaul ◽  
V Setlur ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Multivariate Analysis ◽  
Tumor Size ◽  
Copy Number ◽  
Node Negative ◽  
Node Positive ◽  
Oncogene Amplification ◽  
Her 2 ◽  
Neu Oncogene

PURPOSE To determine prospectively the prognostic significance of HER-2/neu oncogene amplification in the primary tumors of breast cancer patients. METHODS HER-2/neu amplification in tumor DNA was determined by the slot-blot technique in 1,056 patients with breast cancer (stage I to III) diagnosed between 1987 and 1990. Parameters such as estrogen receptor (ER) and progesterone receptor (PgR) levels, tumor size, axillary nodal involvement, tumor grade, and time to relapse were prospectively obtained. RESULTS HER-2/neu oncogene amplification, > or = 2, > or = 3, and > or = 5 copy number, was detected in 21%, 11%, and 7% of patients, respectively. In a test set of 529 patients, Cox multivariate analysis showed HER-2/neu copy number > or = 3 or > or = 5 was associated with shorter disease-free survival (DFS) duration. HER-2/neu copy number > or = 3 correlated significantly with pathologic stage of disease, number of axillary nodes with tumor, histologic type, and absence of ER and PgR. For all patients, after a median follow-up duration of 39 months, Kaplan-Meier univariate analysis indicated that tumor oncogene copy number > or = 3 correlated with shorter DFS in both node-negative and node-positive patients. In Cox multivariate analysis, HER-2/neu copy number > or = 3 was associated with shorter DFS, independent of nodal status, ER level, and tumor size. CONCLUSION Although the follow-up duration of this study is relatively short, we conclude that HER-2/neu amplification is an independent predictor of shorter DFS in both node-negative and node-positive patients.

scholarly journals Excision of metastatic breast cancer from sternum and reconstruction in two patients with solitary metastatic spread

2020 ◽  
Vol 2020 (8) ◽  
Author(s):  
Saifullah Mohamed ◽  
Khurum Mazhar ◽  
Ahmed Osman ◽  
Akshay Patel ◽  
Lakshmi Srinivasan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Previous History ◽  
Metastatic Breast ◽  
Extent Of Resection ◽  
Left Breast ◽  
Term Survival ◽  
Metastatic Breast Carcinoma ◽  
History Of ◽  
Treated Breast

Abstract Metastatic breast carcinoma is a relatively common clinical entity. However, the prognosis of oligometastatic and polygometastatic disease differs considerably pertaining to five-year survival. Metastatic breast carcinoma to the sternum has been described as early as 1988. We describe two cases in our institution who presented with solitary sternal metastases with a previous history of treated breast cancer. In both cases, there had been a history of previous left breast cancer treated aggressively with surgical resection and adjuvant oncological therapy and maintenance hormonal therapy. Partial sternectomy or total sternectomy for solitary metastatic sternal deposits is well established with relatively low morbidity and mortality and improvement in quality of life and possible improvement in long-term survival. Furthermore, reconstructive options are inherently dependent on extent of resection performed. These techniques can incorporate the use of sternal plates in order to approximate defects and reinforce the sternum in the setting of partial sternectomy.

HER-2 status of the primary breast cancer in patients with relapse at least five years after the initial diagnose

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10631-10631
Author(s):  
Z. I. Tomasevic ◽  
D. Jovanovic ◽  
L. Radosevic-Jelic ◽  
Z. Tomasevic ◽  
S. Vasovic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Contralateral Breast ◽  
Late Relapse ◽  
Primary Breast Carcinoma ◽  
Disease Free Interval ◽  
Free Interval ◽  
Her 2 ◽  
Time To Relapse ◽  
Disease Free

10631 Background: HER-2 status of the primary breast carcinoma in the subgroup of patients who relapsed after many years is not well known. The aim of this paper is to determine the HER-2 status of the primary breast cancer in patients with late relapse, defined as local recurrence, distant metastases or carcinoma in the contralateral breast, at least five years after the initial diagnosis Methods: During six month period (June-November 2005) 1256 patients were diagnosed with primary or relapsed breast cancer at the IORS. HER-2 (HercepTest, DAKO) status was determined on the archived pathological specimens of patients with late relapse. Results: One hundred eleven patients (111/1256; 8,8%) were diagnosed with late relapse. At the time of the initial diagnose, majority of patients have been treated for early breast carcinoma. Median age at the initial diagnose was 50 years (33–74). Initial tumor characteristic were: ductal carcinoma 49%; lobular carcinoma 41%;cancer mastitis 6,5%;not reported 3,5%; T1 34%; T2 52%; T3 4,5%; T4 6%;unknown 3,5%; Nodal status: positive 73,5%; negative 23%;not reported 3,5% Steroid receptor status: ER and/or PR positive 59%; both negative 14%; unknown 27%. Median time to relapse is 7 years, (range 5–29), the most frequent first relapse sites were: local recurrence (22%); carcinoma of the contralateral breast (18%); bone metastases (18%). Archived pathological specimens are identified for 63/111 (56,7%) patients and HER-2 status of the those primary breast carcinoma is: 0+ 36,5%; 1+ 34,9%; 2+ 9,5%; 3+ 14,2%; Thirty four patients (30,6%) had disease free interval 10 or more years, and HER-2 3+ in this subgroup is 17,6% (6/34). Conclusions: Long disease free interval in breast cancer patients is usually explained by initial more favorable cancer characteristics. Still, a significant percentage (14,2%) of our patients with median time to relapse of 7 years, initially had breast cancers with HER-2 3+. No significant financial relationships to disclose.

Serial monitoring for circulating cancer cells in blood samples of stage 1–4 breast cancer patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 623-623
Author(s):  
K. H. Tkaczuk ◽  
N. S. Tait ◽  
K. Chua ◽  
F. Feldman ◽  
S. A. Lesko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Receptor Expression ◽  
Breast Cancer Patients ◽  
Blood Samples ◽  
Circulating Cancer Cells ◽  
Her 2 ◽  
Stage 1

623 Serial monitoring for presence, number & characterization of circulating cancer cells (CCC) may provide valuable information that may be relevant to prognosis and treatment outcomes of breast cancer patients (BCP). We conducted a serial blood sampling study at the University of Maryland in BCP with stage 1–4 breast carcinoma. 15–20 ml of venous blood were collected before the start of systemic therapy and periodically thereafter & processed using negative selection method with double-gradient centrifugation & magnetic cell sorting to remove WBCs. Digital images of FITC-positive epithelial cells were acquired with a fluorescence microscope & counted. CCC from 41 patients (Pts) were also stained with Trastuzu-mAb-532 to quantify the HER-2/neu cell surface receptor expression relative to a fluorescence standard. 105 Pts were accrued & 415 blood samples tested (median number of samples/pt; 4 (1–8). During the 24 mos. monitoring period CCC were detected in 57 of 105 pts (54%). The Table below shows that presence of >10 CCC/sample is associated with decreased survival and increased probability of having metastatic disease.(Exact chi-square test for presence vs. absence of metastatses in A, B, C, D groups, P < 0.0001; Fisher’s exact test to compare individual groups: for B vs C+ D, P < 0.001; B vs C, P=0.001). HER-2/neu expression was assessed in CCC of 25 pts (minimum of 4 CCC per sample) as compared with strongly HER-2/neu positive control cell line SKBR-3. 10 Pts were positive & 15 negative for HER-2/neu over-expression in CCC. CCC data & primary tumor data concurred in 6 of 7 Her-2/neu primary tumor tissue positive Pts & in 12 of 13 Her-2/neu primary tissue negative Pts. For 5 Pts tissue data was not available. Conclusions: Increasing CCC numbers/sample appear to correlate with adverse outcome of BCP. Our CCC Test may provide valuable information about prognosis of stage 1–4 BCP. HER-2/neu expression could be quantified in individual CCC & concurred with primary tumor data in 90% of Pts. Supported by NCI Grant CA081903 [Table: see text] [Table: see text]

The effect of trastuzumab therapy on clinical benefit from fulvestrant treatment for metastatic estrogen receptor-positive breast cancer patients.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 155-155
Author(s):  
Mahmoud Charif ◽  
Elyse E. Lower ◽  
Diane Kennedy ◽  
Harriet Kumar ◽  
Shugufta Khan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Metastatic Breast Cancer ◽  
Clinical Benefit ◽  
Primary Tumor ◽  
Endocrine Resistance ◽  
Metastatic Breast ◽  
Primary Tumors ◽  
Duration Of Therapy ◽  
Her 2

155 Background: Overexpression of HER2/neu is associated with tamoxifen resistance in breast cancer (Osborne CK et al. J Natl Canc Inst 2003; 95:353-361). However pts may present with both estrogen receptor (ER) and HER2/neu + tumors. The benefit of adding fulvestrant to trastuzumab is unclear. The objective of the study was to determine the effect of trastuzumab on fulvestrant therapy. Methods: This was an IRB approved record review of patients (pts) from three medical oncologists with biopsy-proven ER+ metastatic breast cancer treated with fulvestrant who also had their primary tumor tested for HER2/neu. Demographic data collected included age at diagnosis, type and stage of cancer, original and metastatic ER, progesterone receptor (PR), and HER-2/neu biomarkers, and site(s) of metastasis, and primary local and systemic treatment. All pts with HER-2/neu + primary tumors received trastuzumab. The duration of fulvestrant therapy was calculated. Time to clinical disease progression on fulvestrant was measured as a surrogate for duration of clinical benefit. Results: Eighty-five metastatic ER+ fulvestrant treated breast cancer pts with known primary tumor HER2/neu status were identified and the duration of therapy calculated. All eleven (13%) pts with documented HER2/neu + primary tumors received trastuzumab. The duration of therapy for HER2/neu + pts (772 (51-1911) days (median (range)) was longer than HER2/neu negative pts (360 (60-2,739) days, p=0.059). The median duration of fulvestrant therapy was 425 days. Pts with HER2/neu + tumors were more likely to be treated beyond the median fulvestrant therapy with an odds ratio of 6.2 (1.26 to 30.92 95% confidence interval, p=0.0249). Conclusions: Trastuzumab plus fulvestrant therapy was associated with a more prolonged clinical response than fulvestrant alone in pts with metastatic breast cancer. This synergism may be due to the effect of trastuzumab inhibiting the activation of transcriptional coactivator MED1, a recently discovered key crosstalk point between HER2/neu and ER signaling pathways in mediating endocrine resistance (Cancer Res 2012;72(21):5625;PLoS One 2013; 8:e70641).

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Science ◽  
1987 ◽  
Vol 235 (4785) ◽  
pp. 177-182 ◽  
Author(s):  
D. Slamon ◽  
G. Clark ◽  
S. Wong ◽  
W. Levin ◽  
A Ullrich ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Her 2 ◽  
Neu Oncogene
Sign in / Sign up

Export Citation Format

Share Document